Best FDA-Cleared Migraine Devices for Adults in 2026

Migraine affects an estimated 40 million people in the United States, and medication is not the right fit for every person. FDA-cleared neuromodulation devices provide drug-free treatment formats that use controlled electrical or magnetic stimulation to influence nerve pathways involved in migraine.

Several FDA-cleared devices are available for adult migraine treatment. They differ in prescription status, age indication, device placement, treatment format, session length, cost, insurance access, and cleared use. The Cefaly device stands out as the best overall option for many adults because it combines prescription-free access, acute and preventive programs, a reusable forehead-worn design, app support, coaching resources, and more than 20 years of Cefaly-specific research.

Key Takeaways

• FDA-cleared migraine devices use different neuromodulation approaches, including external trigeminal nerve stimulation, remote electrical neuromodulation, non-invasive vagus nerve stimulation, combined occipital and trigeminal stimulation, and single-pulse transcranial magnetic stimulation.
• Cefaly is available without a prescription in the U.S., Canada, the EU, and other countries. It includes a 60-minute Acute program and a 20-minute daily Prevent program.
• Cefaly became the first FDA-cleared migraine treatment device for migraine prevention in 2014 and received FDA clearance for acute migraine treatment in 2017.
• Enso for Migraine received FDA clearance on April 16, 2026, for over-the-counter acute and preventive migraine treatment in adults, so older device-count and OTC-count claims may no longer be current.
• Practical differences are more useful than cross-trial efficacy rankings. Patients should compare cleared indications, age requirements, prescription status, placement, treatment routine, warnings, and access.

Understanding FDA-Cleared Migraine Devices

FDA clearance does not mean every device has been evaluated through the same clinical program or can be compared directly using percentages from separate studies. For many Class II devices, the FDA’s 510(k) pathway evaluates whether a device is substantially equivalent to a legally marketed predicate using relevant safety and performance information. Clinical data may be required when necessary.

Neuromodulation devices do not add another medication to a person’s treatment routine. However, side effects, contraindications, warnings, and appropriate use vary by device. A healthcare provider can help determine whether a particular technology fits a person’s diagnosis, medical history, implanted devices, pregnancy status, current medications, and treatment goals.

The descriptions below focus on practical device differences rather than competitor trial outcomes or cross-device efficacy rankings. Study designs, endpoints, populations, and treatment protocols are not directly interchangeable.

How to Compare Migraine Devices

Before choosing a device, consider the following factors:

• Cleared use: Some devices support acute treatment, preventive treatment, or both.
• Prescription status: Some can be purchased without a prescription, while others require clinician authorization.
• Age indication: Adult indications vary, and several devices also include adolescent or pediatric age groups.
• Placement: Devices may be worn on the forehead, upper arm, neck, back of the head, or around the head.
• Treatment routine: Session length and preventive schedules differ substantially.
• Access and cost: Prices, subscriptions, insurance coverage, employer benefits, and VA access can change.
• Safety considerations: Each device has its own contraindications, warnings, and side-effect profile.

1) Cefaly

Best For: Adults seeking a reusable, drug-free device for both acute migraine treatment and daily prevention

Access: Available without a prescription in the U.S., Canada, the EU, and other countries

Treatment Format: Forehead-worn external trigeminal nerve stimulation with a 60-minute Acute program and a 20-minute daily Prevent program

Cefaly is an FDA-cleared external trigeminal nerve stimulation device for adults age 18 and older. It became the first FDA-cleared migraine treatment device for migraine prevention in 2014, received acute-treatment clearance in 2017, and became available over the counter in the U.S. in 2020.

More than 300,000 people have used Cefaly. Its research program includes more than 20 years of research, over 12 clinical trials, 18 peer-reviewed publications, and three pivotal prospective, multicenter, sham-controlled randomized trials.

How Cefaly Works

Cefaly delivers precise electrical impulses through an electrode placed on the forehead, between and just above the eyebrows. This stimulation targets branches of the trigeminal nerve, a major pathway involved in migraine pain. The device connects magnetically to the electrode and allows the user to stabilize stimulation at a strong but comfortable intensity.

The mechanism of action differs from general-purpose body TENS units. Cefaly is designed specifically for external cranial trigeminal nerve stimulation and migraine treatment.

Cefaly Treatment Programs

• Acute program: A 60-minute session used during a migraine attack to support pain relief.
• Prevent program: A 20-minute daily session used consistently for preventive migraine treatment.

Cefaly offers acute migraine relief support during attacks and preventive treatment through daily use. It does not promise immediate relief, guarantee that every attack will stop, or cure migraines.

Cefaly Clinical Results

Cefaly’s clinical studies report the following Cefaly-specific outcomes:

• In the ACME study, 79% of patients experienced a significant reduction in headache pain after one hour of Acute treatment.
• In the PREMICE study, 38.1% of patients achieved a 50% or greater reduction in migraine days after three months of compliant Prevent treatment.
• In the TEAM study, 56.4% of patients reported resolution of their most bothersome migraine symptom after two hours of Acute treatment.

These findings apply to Cefaly and should not be used as direct comparisons with results from other devices. Individual results vary.

Why Cefaly Stands Out

Cefaly combines several patient-focused features in one system:

• Prescription-free access: Adults can purchase Cefaly without completing a prescription step in the U.S., Canada, and EU countries. 
• Two treatment modes: One reusable device supports both acute and preventive treatment routines.
• Migraine-specific design: The forehead electrode targets the trigeminal nerve pathway involved in migraine.
• Research depth: Cefaly has more than 20 years of device-specific research and multiple randomized controlled trials.
• App support: The Cefaly app supports device control, treatment tracking, migraine logging, and compatible wearable integration. Availability and features may vary by region and device model.
• Personal guidance: U.S. and Canadian customers can schedule a free Cefaly Coach session for help with placement, intensity, and routine-building.
• Payment flexibility: Cefaly is HSA/FSA eligible for eligible accounts, with additional financing options available.
• Veteran access: Eligible veterans can review available VA benefits.

Safety and Return Policy

Because Cefaly is drug-free, it does not add medication-related systemic side effects to a person’s migraine routine. Cefaly’s clinical studies report no serious adverse effects. Minor, reversible device-related effects can include sleepiness, post-session headache, forehead redness, nausea, skin irritation, or rare skin allergy.

Do not use Cefaly if you have metallic or electronic implants in the head, a cardiac pacemaker, or an implanted or wearable defibrillator. Do not use it for pain of unknown origin. Talk to a healthcare provider before use if you are pregnant, breastfeeding, have a complex medical history, are changing medications, or are experiencing new or unusual symptoms.

If you are not satisfied with Cefaly, you can return an eligible device for a refund within 90 calendar days of the product delivery date when purchased directly from the official website. Review the full return policy before purchasing.

Who Should Consider Cefaly

Cefaly may be a strong option for the following:

• Adults age 18 and older seeking drug-free acute and preventive treatment
• People who prefer access without a prescription
• People who have difficulty tolerating medication side effects
• People concerned about adding another medication or potential drug interactions
• People seeking one reusable device for both treatment modes
• Eligible veterans exploring VA-covered migraine care

2) Nerivio

Best For: People who prefer an app-controlled device worn away from the head

Access: Prescription required

Treatment Format: Remote electrical neuromodulation armband used for acute and preventive treatment

Nerivio is worn on the upper arm and uses remote electrical neuromodulation rather than direct stimulation of the head or neck. It is indicated for acute and preventive treatment of migraine with or without aura in patients age eight and older.

Key Features

• Worn on the upper arm
• Controlled through a smartphone app
• Used in 45-minute treatment sessions
• Used at migraine onset for acute treatment or every other day for prevention
• Cleared for patients as young as eight

Considerations

Nerivio requires a prescription, and each wearable includes a limited number of treatments before replacement or refill. Insurance coverage varies by plan, location, eligibility, and dispensing pathway.

3) gammaCore

Best For: Patients researching a neck-applied device with several cleared headache indications

Access: Prescription required

Treatment Format: Handheld non-invasive vagus nerve stimulation applied to the side of the neck

gammaCore delivers non-invasive vagus nerve stimulation through the skin on the side of the neck. It is cleared for acute and preventive migraine treatment in patients age 12 and older and also has indications for certain cluster headaches and other primary headache disorders.

Key Features

• Handheld neck placement
• Each stimulation lasts approximately two minutes
• Cleared for acute and preventive migraine treatment
• Includes indications beyond migraine
• May be available through VA pathways for eligible veterans

Considerations

A full treatment may involve more than one stimulation, depending on the indication and dosing instructions. gammaCore requires a prescription, and pricing and coverage vary.

4) SAVI Dual

Best For: Patients who prefer a magnetic-pulse format without adhesive forehead electrodes

Access: Prescription required

Treatment Format: Single-pulse transcranial magnetic stimulation applied at the back of the head

SAVI Dual, formerly known as SpringTMS, uses single-pulse transcranial magnetic stimulation. The device is held against the back of the head and delivers brief magnetic pulses for acute and preventive migraine treatment in patients age 12 and older.

Key Features

• Uses magnetic rather than surface electrical stimulation
• Does not require an adhesive forehead electrode
• Supports acute and preventive treatment routines
• Includes a digital treatment diary
• Accessed through an ongoing prescription program

Considerations

SAVI Dual requires a prescription and uses a monthly access model. Insurance coverage may be limited, and the device is larger than many wearable electrical-stimulation options.

5) Relivion MG

Best For: Adults researching a headset that stimulates both trigeminal and occipital nerve pathways

Access: Prescription required

Treatment Format: Headset-style external combined occipital and trigeminal neurostimulation

Relivion MG wraps around the head and places electrodes on the forehead and the back of the head. It is FDA-cleared for the acute treatment of migraine with or without aura in adults age 18 and older.

Key Features

• Stimulates trigeminal and occipital nerve pathways
• Headset design with front and rear electrodes
• App-supported treatment and tracking
• Designed for at-home acute migraine treatment

Considerations

Relivion is cleared for acute treatment rather than preventive treatment. It requires a prescription, and access follows a program-based pricing model. Patients should confirm current fees, refund terms, and ongoing costs directly before enrolling.

6) HeadaTerm 2

Best For: Adults researching an over-the-counter forehead device for episodic migraine prevention

Access: No prescription required

Treatment Format: Forehead-worn external trigeminal nerve stimulation for preventive treatment

HeadaTerm 2 is an OTC forehead-worn e-TNS device cleared for the preventive treatment of episodic migraine in adults age 18 and older. It delivers electrical stimulation to the supraorbital and supratrochlear nerve region and allows users to adjust intensity.

Key Features

• Available without a prescription
• Forehead placement
• Adjustable stimulation intensity
• Cleared specifically for preventive treatment of episodic migraine

Considerations

HeadaTerm 2 is not cleared for acute migraine treatment. Current pricing and market availability should be verified with the manufacturer or an authorized seller.

7) Enso for Migraine

Best For: Adults whose health plan or employer offers Hinge Health’s migraine program

Access: FDA-cleared for over-the-counter use; current access may depend on program eligibility and distribution

Treatment Format: App-controlled forehead stimulation for acute and preventive migraine treatment

The FDA cleared Enso for Migraine on April 16, 2026. The device is indicated for acute treatment of migraine with or without aura and preventive treatment of migraine in adults age 18 and older who have been diagnosed with migraine by a physician.

Enso uses a forehead gel pad and app-controlled transcutaneous electrical stimulation. Its FDA documentation identifies Cefaly Connected OTC as the predicate device.

Key Features

• FDA-cleared for OTC use
• Intended for both acute and preventive treatment
• Forehead placement
• App-controlled treatment
• Integrated into Hinge Health’s Migraine Care program

Considerations

FDA clearance for OTC use does not necessarily mean the device is available through ordinary direct-to-consumer retail channels. Access may depend on employer benefits, health-plan participation, clinical eligibility, and Hinge Health program availability.

Why Cefaly Is the Best Overall Choice for Many Adults

Cefaly is not the only FDA-cleared or OTC migraine device, but it remains the strongest overall option to feature for many adult patients because it combines mature research, prescription-free access, dual treatment modes, a reusable migraine-specific e-TNS device, app-enabled tracking, coaching support, HSA/FSA eligibility, and an established direct-purchase pathway.

Prescription-Free Access

Cefaly is available without a prescription in the U.S., Canada, the EU, and other countries. This makes it possible for eligible adults to explore a migraine-specific medical device without first navigating a prescription process. Regional product and app availability may differ.

One Device for Acute and Preventive Treatment

Cefaly’s 60-minute Acute program supports treatment during a migraine attack, while its 20-minute daily Prevent program supports preventive treatment over time. This dual-mode format allows one reusable device to address two distinct migraine-management needs.

Cefaly-Specific Clinical Evidence

Cefaly’s evidence base includes more than 20 years of research, over 12 clinical trials, 18 peer-reviewed publications, and three pivotal randomized controlled trials. These studies evaluate Cefaly on its own terms without relying on cross-device comparisons.

Support Beyond the Device

Cefaly customers can use the app, coaching program, treatment education, troubleshooting resources, and optional electrode subscription to support consistent use. The migraine tracker can also help users organize treatment routines and migraine patterns.

Flexible Payment and Refund Options

Eligible customers may use HSA or FSA funds, explore financing, and review commercial insurance information. Direct purchases may qualify for the 90-day refund policy described above.

Frequently Asked Questions

What does FDA clearance mean for a migraine device?

For many Class II migraine devices, FDA clearance means the agency determined that the device is substantially equivalent to a legally marketed predicate for its intended use based on relevant safety and performance information. Clinical data may be required when necessary, but clearance does not mean every device has undergone identical trials or can be compared using separate study percentages.

Are all FDA-cleared migraine devices available without a prescription?

No. Prescription requirements vary. Cefaly and HeadaTerm 2 are available without a prescription, and Enso for Migraine was cleared for OTC use in 2026. Nerivio, gammaCore, SAVI Dual, and Relivion require prescriptions. Commercial availability can also differ from regulatory status.

Can migraine devices be used for both acute treatment and prevention?

Some can. Cefaly, Nerivio, gammaCore, SAVI Dual, and Enso have acute and preventive treatment indications. Relivion is cleared for acute treatment, while HeadaTerm 2 is cleared for prevention. Always confirm the current indication and instructions for the specific device model.

Do neuromodulation devices have side effects?

They can. Side effects, warnings, and contraindications vary by technology and device. Cefaly’s clinical studies report no serious adverse effects, while minor reversible effects can include sleepiness, post-session headache, forehead redness, nausea, skin irritation, or rare skin allergy. Review the manufacturer’s safety information and discuss concerns with a healthcare provider.

Can Cefaly be used with migraine medication?

Cefaly is drug-free and can be considered part of a broader migraine-management plan. Do not stop or change medication without medical guidance. A healthcare provider can help assess how Cefaly fits alongside current acute or preventive treatments.

Is Cefaly suitable during pregnancy or with an implanted device?

Talk to a healthcare provider before using Cefaly if you are pregnant or breastfeeding. Do not use Cefaly if you have metallic or electronic implants in the head, a cardiac pacemaker, or an implanted or wearable defibrillator. Review the support center for additional guidance.

How should someone choose between migraine devices?

Start with the cleared indication, prescription requirement, age range, device placement, treatment schedule, safety information, cost, and access pathway. A healthcare provider can help match those factors to individual needs. You can also use Cefaly’s directory to find a certified provider.